News
IVF first or IUI first? A large NEJM trial puts numbers on the trade-off
· IVF Automation News
Summary
A randomised trial of 737 couples in New Zealand, published in the New England Journal of Medicine on 27 October 2026, found that up to four cycles of IUI with ovarian stimulation were not non-inferior to one complete IVF cycle: 31% vs 55% cumulative live birth in the first seven months. Once couples could move on to further IVF, cumulative live birth was similar (70% vs 71%). The results test ESHRE's IUI-first recommendation and give clinics clearer numbers for counselling.
For years, the standard advice for couples with unexplained infertility has been to start with intrauterine insemination (IUI) and move to IVF only if that fails. A randomised trial from New Zealand, published online in the New England Journal of Medicine on 27 October 2026, puts a number on what that sequence costs in time. It also shows that, given enough time, couples tend to end up in a similar place.
What did the FIIX trial test?
The FIIX trial was led from the University of Auckland, with co-authors from fertility clinics in Auckland, Wellington and Christchurch. It randomised 737 couples with unexplained infertility. Of these, 365 were assigned to IUI with ovarian stimulation first and 372 to IVF first. One couple in the IVF group later withdrew consent for use of their data.
The trial ran in two stages:
- Stage 1 (7 months): up to four cycles of IUI with ovarian stimulation, or one complete IVF cycle, including transfer of all embryos from that cycle.
- Stage 2: couples without a live birth or ongoing pregnancy could continue. The IUI group could have up to two IVF cycles, and the IVF group one more IVF cycle.
Stage 1 was designed as a non-inferiority test. The question was whether IUI would be no more than 10 percentage points worse than IVF on cumulative live birth.
What did it find?
In stage 1, IUI fell well short. The cumulative live-birth rate was 31% (89 of 288 couples) with IUI and 55% (164 of 297) with IVF. The adjusted difference was −24 percentage points (95% CI −31 to −16), so IUI did not meet the non-inferiority test. Couples who were in stage 1 during COVID-19 lockdowns were left out of this primary analysis, which is why it covers 585 couples rather than all 737.
Over both stages, the gap closed. Among all randomised couples who gave consent, cumulative live birth was 70% (257 of 365) with IUI first and 71% (265 of 371) with IVF first. The adjusted difference was 0 percentage points (99% CI −9 to 8). Live births counted towards stage 2 if the treatment cycle or last period began within 20 months of randomisation.
Safety: serious adverse events occurred in 6 couples in the IUI group and 14 in the IVF group. Most were linked to egg retrieval or ovarian hyperstimulation.
Why does this matter if guidelines already recommend IUI first?
Because the guideline rests on thin evidence. The 2023 ESHRE guideline on unexplained infertility states that “IUI with ovarian stimulation is recommended as a first-line treatment for couples with unexplained infertility”. It adds that “IVF is probably not recommended over IUI with ovarian stimulation”, with any decision to use IVF individualised by age, duration of infertility, previous treatment and previous pregnancy. The FIIX authors note that evidence comparing the two approaches directly has been limited. Their trial adds a large randomised comparison.
In short, the data do not show that one pathway is simply better. IVF first got more couples to a baby within the first seven months. IUI first got a similar share of couples there in the end, but it took longer. Fewer serious adverse events were recorded in the IUI-first group, although the abstract gives no statistical test for that comparison.
What does it mean for IVF labs and clinics?
- Clinic owners and specialists: counselling on “IUI or IVF first” can now point to randomised figures on both speed and the final outcome. How much time a couple has, especially given the woman's age, is central to that choice. That is a clinical decision for the treating doctor and the couple.
- Lab managers: any shift towards IVF first means more retrievals, cultures and frozen embryos per patient sooner. It is worth modelling the effect on incubator space, embryologist hours and cryostorage before it shows up in the schedule. Our free IVF lab KPI calculator can help with that baseline.
- Embryologists: the trial's IVF arm involved transferring all embryos from one complete cycle, including frozen ones, so frozen embryo transfer workflows and freezing outcomes matter as much as the fresh transfer. The same ESHRE guideline also states that ICSI is not recommended over conventional IVF in couples with unexplained infertility.
Does it apply to India?
FIIX enrolled couples who had been accepted for publicly funded fertility treatment in New Zealand. Indian clinics work under different funding, pricing and patient-pathway conditions, so the results cannot simply be transferred. The trial does give Indian clinics a cleaner basis for discussing trade-offs. Clinics that track cumulative outcomes per couple, not just per cycle, will be better placed to see how their own IUI-to-IVF pathway compares. Clinics reviewing their IUI and IVF services may also want to check their obligations under the ART (Regulation) Act, 2021, using our ART Act checklist.
What is the commercial outlook?
If more clinicians and patients choose IVF first for unexplained infertility, demand would move towards IVF lab capacity, consumables and freezing. Demand for IUI-related services would fall. One trial is unlikely to change guidelines overnight, and the cumulative result gives support to both pathways. For vendors of lab automation, scheduling and outcome-tracking software, the most immediate use case is helping clinics measure time to live birth across a full patient journey. Our guide to IVF lab KPI dashboards covers how to set that up.
What we could not verify
We worked from the NEJM abstract as indexed on PubMed; the trial was also presented as a conference abstract at ESHRE 2025 (O-289). We did not have the full paper, so details such as subgroup results by age and costs are not covered here. We have not quoted any of the investigators.
Sources
- Prentice LR, Sadler LC, … Farquhar CM. In Vitro Fertilization or Intrauterine Insemination in Unexplained Infertility. N Engl J Med, published online 27 Oct 2026 (peer-reviewed RCT; PubMed abstract, PMID 42950222). https://pubmed.ncbi.nlm.nih.gov/42950222/
- Same article, publisher DOI (NEJM; paywalled). https://doi.org/10.1056/NEJMoa2602728
- IVF.net Newsdesk, “IUI not non-inferior to one complete IVF cycle in unexplained infertility…”, 30 Oct 2026 (news report). https://ivf.net/ivf/iui-not-non-inferior-to-one-complete-ivf-cycle-in-unexplained-infertility-with-no-significant-o14158.html
- ESHRE Guideline Development Group. Evidence-based guideline: unexplained infertility, Human Reproduction 2023;38(10):1881 (guideline; PubMed 37599566). https://pubmed.ncbi.nlm.nih.gov/37599566/
- ESHRE, Unexplained infertility guideline, full text PDF, 2023 (guideline). https://www.eshre.eu/-/media/sitecore-files/Guidelines/UI/UI-guideline_-Final.pdf
- FIIX study abstract O-289, Human Reproduction 2025;40(Suppl 1), ESHRE 2025 (conference abstract). https://doi.org/10.1093/humrep/deaf097.289
- The FIIX Study, University of Auckland (trial website; registry ACTRN12619001003167). https://thefiixstudy.auckland.ac.nz/
Tags: FIIX trial, IVF vs IUI, unexplained infertility, intrauterine insemination, ovarian stimulation, NEJM 2026, ESHRE guideline, IVF lab capacity, India IVF
Information only, not medical advice.